How about the drug Relugolix?

Relugolix is currently the only oral GnRH antagonist approved for the treatment of advanced prostate cancer and is a once-daily treatment. In Phase II and III studies, regaglic achieved rapid and sustained castration without the testosterone surge associated with LHRH agonists, thereby avoiding the potential clinical consequences of tumor recurrence and the need for concomitant anti-androgen therapy. Repagolic also achieves rapid recovery of testosterone, which may reduce adverse events associated with androgen deprivation therapy and provide opportunities for combination and intermittent treatment strategies.

Data fromthe Phase III HERO study showed that the GnRH antagonistrepagliflozin improved cardiac safety compared with the LHRH agonist leuprolide, including a significant reduction in the risk of major adverse cardiovascular events. Taken together, the data suggest that repagliflozin may alleviate some of the cardiovascular problems associated with androgen deprivation therapy and may become a new standard of care for men with prostate cancer. In summary, repagliflozin represents a new and recently available prostate cancer treatment strategy that combines the mechanistic advantages of GnRH antagonists with the potential benefits of oral delivery.

The original drug of Regogliflox has not yet been launched in the country, so it is not covered by medical insurance. There are European and Japanese versions of the original drug Rleglik available overseas. The ingredients of the two are basically the same. The price of the European version of 120mg*30 tablets per box may be around RMB 4,000, and the price of the Japanese version of 40mg*100 tablets per box may be around RMB 4,000 (the price may fluctuate due to exchange rates). Currently, there are no generic versions of Repagliflox produced and put on the market.